Routine screening for BI-RADS 3 lesions reduces the recall rate and is unlikely to result in adverse outcome
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.